Your AI-Trained Oncology Knowledge Connection!
Although there has been in increase in promising novel regimens available for patients with breast cancer in recent years, oncologists should carefully consider whether each agent would provide a significant enough benefit to offset its associated toxicities, cost, and the time and commitment by the patient it requires.
Denise A. Yardley, MD, discusses two novel agents on the horizon for HER2-positive breast cancer.
Shirish Gadgeel, MD, discusses the KEYNOTE-021 and KEYNOTE-189 studies, which are both examining pembrolizumab with chemotherapy in patients with non–small cell lung cancer.
Raffaele Califano, MD, discusses the KEYNOTE-028 and CheckMate-032 trials, the role of PD-L1 as a biomarker in small cell lung cancer, and what is on the horizon for immunotherapies in the landscape of SCLC.
Hendrik-Tobias Arkenau, MD, PhD, discusses the significance of the JAVELIN results for gastrointestinal cancer, the potential for CTLA-4 and PD-1/PD-L1 combinations, and the promise of pembrolizumab (Keytruda) in colorectal cancer.
The debate between the phase III CALGB/SWOG 80405 and FIRE-3 studies has been settled, as findings of a retrospective analysis of 80405 show that tumor location is significant in determining survival outcomes for patients with KRAS wild-type metastatic colorectal cancer.
Michele Cavo, MD, provides insight on the results of the randomized phase III European Myeloma Network EMN02/HO95 MM trial for multiple myeloma.
The FDA has approved the cobas HPV Test for use with SurePath Preservative Fluid for the detection of human papilloma virus (HPV) in cervical cells.
The FDA has issued two draft guidances that will provide regulatory oversight for the use of next-generation sequencing-based tests.
Bone metastases in castration-resistant prostate cancer create a significant problem, and a rising incidence of men are developing advanced disease.
A phase III trial investigating the first-in-class immunotherapy vaccine nelipepimut-S (NeuVax) for the prevention of recurrence in early-stage breast cancer has been stopped due to futility.
Ranee Mehra, MD, discusses what the KEYNOTE-012 findings could mean for patients, the growing role for the immunotherapy agent in head and neck cancer, and what else is on the horizon for the treatment landscape.
Morganna Freeman, DO, explains the impact of hedgehog inhibitors in basal cell carcinoma, the ideal patient to receive them, and emerging agents on the horizon for treatment of the disease.
Ryan J. Sullivan, MD, discusses which patients are at risk for advanced basal cell carcinoma, current standard therapies, and options for those who relapse after treatment with hedgehog/smoothened inhibitors.
Francesco Forconi, MD, discusses his research into the B-cell receptor structure and its function in chronic lymphocytic leukemia.
In metastatic castration-resistant prostate cancer, pain and hemoglobin levels, PSA levels, and ECOG performance status may predict which patients will be able to receive the recommended 6-dose regimen of radium-223 dichloride (Xofigo).
Richard G. Stock, MD, discusses the ideal patient for radium-223 dichloride (Xofigo), its proper sequencing with metastatic castration-resistant prostate cancer, and the future outlook for the therapy.
David F. McDermott, MD, provides further insight on the long-term efficacy and safety of nivolumab and its role in renal cell carcinoma, as well as potential combination regimens and challenges with sequencing nivolumab.
Inotuzumab ozogamicin demonstrated significantly improved progression-free survival and complete remission rates compared with chemotherapy for patients with relapsed or refractory acute lymphoblastic leukemia.
Final 5-year efficacy and safety data from the phase III COMFORT-I trial confirm previous findings that ruxolitinib confers a significant benefit in patients with intermediate-2 and high-risk myelofibrosis.
Tyrosine kinase inhibitors can safely be halted in select patients with chronic phase chronic myeloid leukemia followed a maintained deep molecular remission.
Keith T. Flaherty, MD, discusses choosing between immunotherapy and targeted therapy in the frontline setting for patients with BRAF-mutated melanoma.
An analysis of over 28,000 patients younger than 65 with incurable cancers found that approximately three-fourths of them received aggressive care within the last 30 days of life and one-third died in the hospital.
Adding daratumumab to bortezomib and dexamethasone reduced the risk of progression or death by 61%, and doubled response rates compared with the standard 2-drug regimen alone for patients with recurrent or refractory multiple myeloma.
Treating patients based on the presence of molecular abnormalities regardless of tumor type proved to be a promising strategy in an ongoing phase IIa umbrella basket study.
Precancerous colon polyps exhibit many of the same driver mutations that fuel the development of colorectal cancer.
Keith C. Bible, MD, PhD, discusses novel treatments he is excited about, the role of lenvatinib, and what the future may hold for thyroid cancer treatment.
James Melotek, MD, discusses two clinical trials looking at the impact of cetuximab in patients with squamous cell carcinoma of the head and neck.
Sumanta Kumar Pal, MD, provides insight on the FDA approval of the TKI lenvatinib in combination with everolimus, an mTOR inhibitor as a treatment for patients with advanced RCC following prior antiangiogenic therapy.
Robert Ferris, MD, PhD, explains the potential of nivolumab, its future, and its limitations in the treatment of patients with head and neck cancer.
